The overall goal of this biospecimen procurement core is the collection, maintenance, and distribution of high quality biologic samples from a spectrum of prostate cancer and control patients, along with collection of accurate linked clinical and pathologic data on these samples. The Robert H. Lurie Comprehensive Cancer Center's Specialized Program of Research Excellence (SPORE) in prostate cancer consists of three prostate cancer treatment centers; Northwestern Memorial Hospital (NMH), NorthShore University HealthSystem (NS/UC), and the University of Chicago (UC). Because these institutions see large numbers of new prostate cancer patients from a spectrum of socioeconomic and ethnic groups, with over 500 annual radical prostatectomies performed, our access to patient derived tissues for research is high and diverse. NMH and NS/UC have successfully implemented sample procurement to support the prostate SPORE efforts and collectively, these facilities have procured samples on more than 4,500 patients since 2001. Samples (tissue, serum, DNA, RNA, and TMAs) and data have been provided for 98 studies to date and plans are underway to integrate specimen collection at UC. The Robert H. Lurie Comprehensive Cancer Center Pathology Core Facility (RHLCCC-PCF), a shared resource of the RHLCCC, is independent of but complements the tissue procurement by providing research histology expertise. This core will continue the collection of fixed embedded and fresh frozen tissues, urine, blood and blood components, as well as the acquisition and database storage of essential pathologic and clinical information needed for conducting translational research. Additionally, the facility has constructed and will continue to construct numerous tissue microarrays to suit the needs of SPORE investigators. This resource benefits not only our SPORE investigators, but facilitates research activities of scientists within and outside the parent institutions. This process is supervised by a Sample Review and Disbursement Committee, (including physicians, pathologists and a patient advocate), the SPORE Executive Committee, and is reviewed by the individual Institutional Review Boards (IRBs) on an annual basis.

Public Health Relevance

CORE C NARRATIVE The collection of well-annotated biologic samples is critical to advance the mission of the SPORE in Prostate Cancer to improve our understanding of the biology of prostate cancer, to distinguish lethal disease and to develop novel therapies for this disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA180995-02
Application #
9128681
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2016-08-01
Budget End
2017-07-31
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Northwestern University at Chicago
Department
Type
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Szmulewitz, Russell Z; Peer, Cody J; Ibraheem, Abiola et al. (2018) Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol 36:1389-1395
Fong, Ka-Wing; Zhao, Jonathan C; Song, Bing et al. (2018) TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression. Nat Commun 9:5007
Giri, Veda N; Knudsen, Karen E; Kelly, William K et al. (2018) Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol 36:414-424
Anker, Jonathan F; Mok, Hanlin; Naseem, Anum F et al. (2018) A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer. J Vis Exp :
Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999
Pascal, Laura E; Wang, Yao; Zhong, Mingming et al. (2018) EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer. Neoplasia 20:351-363
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Anker, Jonathan F; Naseem, Anum F; Mok, Hanlin et al. (2018) Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. Nat Commun 9:1591
Zang, Yachen; Pascal, Laura E; Zhou, Yibin et al. (2018) ELL2 regulates DNA non-homologous end joining (NHEJ) repair in prostate cancer cells. Cancer Lett 415:198-207
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680

Showing the most recent 10 out of 67 publications